Two years on. She says every few months she has a step change which takes her to a better place.

Anyone from mjff, is there no way we can get this to market quicker ?

Neil.

http://t.co/LhmUms4iOw

http://uk.reuters.com/article/2011/1...7NF1RO20111215

the company seems to have gone back to the drawing board? hard to get a handle on what the status of prosavin is.

According to this update from Oxford Biomedica in 2012 she was not an exception. All 15 patients improved probably to various degrees.

http://www.biotechnology-europe.com/...%20Disease.htm

You're not wrong when you say it is hard to get a handle on the status of Prosavin.

However your article is old dated 15 December 2011 and has been superseded by the following positive high profile press release dated 12 April 2012

http://news.sky.com/story/9567/revol...for-parkinsons

Now the company are bullish about partnering to progress Prosavin, however words are cheap. It is claimed that the disappointing results of the higher doses was due to a non optimal delivery mechanism which has been overcome. This seems like a good science companŷ with appalling commercial people. Every now and then it sends press releases to sky tv and then ....nothing happens ... Infuriating company.

Neil.

i read their 2013 report under their investor website, no partner mentioned yet,
http://www.oxfordbiomedica.co.uk/upl...b-agm-2013.pdf

they are partnering with SANOFI on other products.

the patient is much improved, the question is she doing better than a DBS?

that seemed to be the issue with neurologix?

it's great that she says she's gradually improving which is definately better than DBS but she didn't look or sound any better just sitting there compared to previous video of her after the operation and one would think if many more patients were also improving you'd hear about it. she said she is taking fewer meds but like you say, talk is cheap.

just playing devil's advocate, one would assume MJFF, big pharma is following them closely, maybe they aren't ready to partner?

Medtronic were shareholders in neurologix and while I agree the results were about equal between DBS and neurologix I know which I would rather have. I assume Medtronic were supporting their vested interest in this one however that, as they say, is history.

I don't find it unusual that one person appears to be fronting the results however I do agree that the inability to produce a partner is starting to smell.

IMHO, no partner by the end of the year then we are looking at smoke and mirrors.

Take care,
Neil.

it is interesting no patient who received the GAD gene from neurologix has spoken publicly as far as i know.

http://query.nytimes.com/gst/fullpag...55C0A96E9C8B63

It guess it all comes to profit. If after this procedure patients is able to reduce medication intake it means less pills sold and less money for the big pharma. Sheila might be showing better results then others but she apparently cut her medication in half and is as per own testimony functioning better then before the procedure.

to cure cancer, diabetes, alzheimers.
i think they are investing less in pd partly because hard to find volunteers for clinical trials and bigger fish to fry. DBS was discovered by chance. amazing what cancer treaments that might work cost.

but i agree, society could save billions in pd healthcare costs and lost productivity and get a good return on investing in the "cures"? before alzheimers bankrupts us?